Showing 3061-3070 of 5646 results for "".
- Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Greater Sensitivity than Dilated Examshttps://modernod.com/news/study-finds-eyenuk-artificial-intelligence-detects-diabetic-retinopathy-with-greater-sensitivity-than-dilated-exams/2481158/Eyenuk announced the publication of EyeArt validation results in Ophthalmology Science, a peer-reviewed journal of the American Academy of Ophthalmology. The study, titled “Artifici
- First Dry Eye Disease Education Initiative Event from World Council of Optometry and Alcon Set for November 8https://modernod.com/news/first-dry-eye-disease-education-initiative-event-from-world-council-of-optometry-and-alcon-set-for-november-8/2481153/The
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r
- eSight Assistive Device for Visually Impaired Available for Demonstrations at AAOhttps://modernod.com/news/esight-assistive-device-for-visually-impaired-available-for-demonstrations-at-aao/2481104/Vision enhancement platform,
- Shamir Glacier PLUS Metaform on 1.6 and 1.67 Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-16-and-167-now-available/2481093/Shamir announced the availability of the new Glacier PLUS Metaform lens-coating technology, which uses fewer resources and chemicals in its production than its premium AR coating, making it an eco-friendly option for consumers. According to Shamir, features of the new len
- Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoptionhttps://modernod.com/news/neurolens-raises-67-million-investment-to-develop-new-products-and-accelerate-adoption/2481080/Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wac
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL
- Zeiss Integrated Workflow Solutions Designed to Create Digital Transformation in Health Carehttps://modernod.com/news/zeiss-integrated-workflow-solutions-are-creating-the-digital-transformation-in-health-care/2481054/At Zeiss Innovation Week, taking place September 6-8, 2022, Zeiss Medical Technology will host experts in ophthalmology to share their personal experiences of how the power of integrated workflow solutions, data management, and a range of new software applications enable improved efficiencies and